Allogene Therapeutics (ALLO) Net Equity Issued and Repurchased (2018 - 2026)

Allogene Therapeutics has reported Net Equity Issued and Repurchased for 6 years, with the latest figure at $20.7 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 106.64% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.7 million (down 36.38% YoY) and the FY2024 annual result came in at $6.8 million, down 92.58% from the prior year.
• Net Equity Issued and Repurchased grew to $20.7 million in Q1 2026 per ALLO's latest filing, from -$11.5 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $105.3 million in Q2 2024 and troughed at -$104.3 million in Q3 2024.
• A 4-year average of $14.8 million and a median of $7.9 million in 2024 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased slumped 98.56% in 2025, then jumped 106.64% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at $91.1 million in 2023, then plunged by 93.7% to $5.7 million in 2024, then plunged by 300.52% to -$11.5 million in 2025, then soared by 279.47% to $20.7 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $20.7 million, -$11.5 million, and $1.5 million for Q1 2026, Q3 2025, and Q2 2025 respectively.